Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors.

BMD006 is an inhaled mRNA tumor-associated antigen dry powder vaccine targeting lung cancer and solid tumors with lung metastasis, classified as an off-the-shelf anti-tumor product. The product contains two clinically validated TAA antigen combinations: for patients with solid tumors that have lung metastasis, the mRNA vaccine consists of four mRNA sequences encoding melanoma-associated tumor antigens ; for patients with primary lung cancer, the mRNA vaccine consists of six mRNA sequences encoding tumor-associated antigens of primary lung cancer . This study is a single-center, open-label, do

Trial Details

NCT ID
NCT06928922
Phase
EARLY_PHASE1
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • BMD006 monotreatment
  • BMD006 in combination with PD-1 antibody
  • BMD006 in combination with PD-1/VEGF antibody
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Able to understand and comply with the requirements of the study protocol, voluntarily participate in the trial, and sign a written informed consen…
  • Must be at least 18 (inclusive) at the time of signing the ICF, and both male and female participants are eligible.
  • Histologically or cytologically confirmed as advanced lung cancer (driver gene negative) or advanced solid tumors with lung metastasis, and having …
  • Agree to provide fresh tumor tissue samples or archived tumor tissue samples within the past three years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →